Clinical Trials

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07535437 2026-04-17

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06741085 2026-04-13

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

56 enrolled

Non Small Cell Lung Cancer Metastatic

NCT03410043 2026-04-06

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03586453 2026-04-03

Osimertinib In EGFR Mutant Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT07505173 2026-04-01

HOPE-WBRT

74 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04762199 2026-03-31

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

69 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03433469 2026-03-30

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07486648 2026-03-24

Precision

53 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07485452 2026-03-20

OSIBBBOOST

7 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

8 enrolled

Lung Neoplasms

NCT05401110 2026-03-04

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07375316 2026-02-10

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

216 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04743505 2026-01-20

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05089916 2026-01-14

ROSE

42 enrolled

NSCLC

NCT04769388 2026-01-12

FLAME

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04563871 2026-01-09

BLOSSOM

73 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

22 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07153055 2025-12-18

LOTS

16 enrolled

Small Cell Lung Carcinoma

NCT04780568 2025-12-09

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

24 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07058519 2025-11-26

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

250 enrolled

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

NCT05017025 2025-11-19

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

32 enrolled

Lung Neoplasms

NCT03122717 2025-11-12

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04410796 2025-11-06

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

571 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03667820 2025-11-04

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

41 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04695925 2025-10-15

TOP

294 enrolled

Non-small Cell Carcinoma

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Phase NA Recruiting

100 enrolled

CNS

Meningeal Carcinomatosis

NCT07177092 2025-09-16

SURGAN-TKI

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Phase 1 Active not recruiting

NSCLC

NCT03567642 2025-07-03

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

11 enrolled

Lung Neoplasms

NCT04591002 2025-06-26

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

43 enrolled

Lung Neoplasms

NCT07038460 2025-06-26

NEO-LISI

134 enrolled

Resectable Non-small Cell Lung Cancer

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Phase EARLY_PHASE1 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

17 enrolled

Phase NA Active not recruiting

Lung Neoplasms

NCT03969823 2025-05-15

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

148 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06014827 2025-05-04

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

32 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04141644 2025-04-16

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT06918782 2025-04-09

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

47 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05298176 2025-03-28

COMBINATION

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03543683 2025-02-27

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

115 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05281406 2025-02-21

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06827145 2025-02-14

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC